Related Experiment Video
Updated: Feb 10, 2026

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
Aastha Arora1,2, Vikas Bhuria3, Puja P Hazari1
1Institute of Nuclear Medicine & Allied Sciences, New Delhi, India.
Abstract:
Bleomycin (BLM) is an effective curative option in the management of several malignancies including pleural effusions; but pulmonary toxicity, comprising of pneumonitis and fibrosis, poses challenge in its use as a front-line chemotherapeutic. Although Amifostine has been found to protect lungs from the toxic effects of radiation and BLM, its application is limited due to associated toxicity and unfavorable route of administration. Therefore, there is a need for selective, potent, and safe anti-fibrotic drugs. The current study was undertaken to assess the protective effects of DRDE-30, an analog of Amifostine, on BLM-induced lung injury in C57BL/6 mice. Whole body micro- computed tomography (CT) was used to non-invasively observe tissue damage, while broncheo-alveolar lavage fluid (BALF) and lung tissues were assessed for oxidative damage, inflammation and fibrosis. Changes in the lung density revealed by micro-CT suggested protection against BLM-induced lung injury by DRDE-30, which correlated well with changes in lung morphology and histopathology. DRDE-30 significantly blunted BLM-induced oxidative stress, inflammation and fibrosis in the lungs evidenced by reduced oxidative damage, endothelial barrier dysfunction, Myeloperoxidase (MPO) activity, pro-inflammatory cytokine release and protection of tissue architecture, that could be linked to enhanced anti-oxidant defense system and suppression of redox-sensitive pro-inflammatory signaling cascades. DRDE-30 decreased the BLM-induced augmentation in BALF TGF-β and lung hydroxyproline levels, as well as reduced the expression of the mesenchymal marker α-smooth muscle actin (α-SMA), suggesting the suppression of epithelial to mesenchymal transition (EMT) as one of its anti-fibrotic effects. The results demonstrate that the Amifostine analog, DRDE-30, ameliorates the oxidative injury and lung fibrosis induced by BLM and strengthen its potential use as an adjuvant in alleviating the side effects of BLM.
Insights
DRDE-30, an Amifostine analog, protects lungs from bleomycin (BLM)-induced injury by reducing oxidative stress, inflammation, and fibrosis. This study highlights DRDE-30
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Toxicology
Background:
- Bleomycin (BLM) is effective against malignancies but causes lung toxicity (pneumonitis, fibrosis).
- Amifostine offers lung protection but has limitations (toxicity, administration route).
- There is a need for safer, effective anti-fibrotic agents to mitigate BLM-induced lung injury.
Purpose of the Study:
- To evaluate the protective effects of DRDE-30, an Amifostine analog, against bleomycin-induced lung injury in mice.
- To assess DRDE-30's impact on oxidative stress, inflammation, and fibrosis in the lungs.
Main Methods:
- Bleomycin-induced lung injury model in C57BL/6 mice.
- Whole-body micro-computed tomography (micro-CT) for non-invasive assessment of lung damage.
- Analysis of bronchoalveolar lavage fluid (BALF) and lung tissues for oxidative stress, inflammation, and fibrosis markers.
Main Results:
- Micro-CT revealed DRDE-30 protected against BLM-induced lung density changes, correlating with improved lung morphology.
- DRDE-30 significantly reduced BLM-induced oxidative stress, inflammation (MPO activity, cytokines), and fibrosis (hydroxyproline, α-SMA expression).
- DRDE-30 suppressed epithelial-to-mesenchymal transition (EMT) and enhanced antioxidant defense systems.
Conclusions:
- DRDE-30 effectively ameliorates bleomycin-induced lung injury and fibrosis.
- DRDE-30 demonstrates potential as an adjuvant therapy to reduce BLM-related pulmonary toxicity.
- The findings support DRDE-30's development as a selective and safe anti-fibrotic agent.
More Related Videos
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

